Drug Approval | October 19, 2021
Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company claims that its Empagliflozin tablets are the most affordable in India
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
Equity raise to finance growth and investments in the biological space
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
